NPPA panel pegs price of Hetero Labs HIV drug Darunavir Ethanolate at Rs 190.44 per tablet
New Delhi: The National Pharmaceutical Pricing Authority (NPPA) Committee has suggested the retail price of each film-coated tablet containing Darunavir Ethanolate, which is equivalent to Darunavir IP 800 mg plus Ritonavir IP 100 mg, at Rs. 190.44 per tablet excluding GST, manufactured by Hetero Labs Ltd. and marketed by Cipla Ltd.
This came after the Multidisciplinary Committee of Experts deliberated on the retail price fixation of the popular protease inhibitor Darunavir Ethanolate, which is used to treat HIV.
Darunavir Ethanolate is the ethanolate form of darunavir, which is a human immunodeficiency virus type 1 (HIV-1) protease nonpeptidic inhibitor. Darunavir, in general, is used with other HIV protease inhibitor drugs as well as ritonavir for the effective management of HIV-1 infection.
Darunavir specifically targets and binds to the active site of HIV-1 protease after oral administration, inhibiting dimerization and catalytic activity of HIV-1 protease.In HIV-infected cells, this suppresses the proteolytic cleavage of viral Gag and Gag-Pol polyproteins. This suppression results in the synthesis of immature, non-infectious viral proteins that are unable to form mature virions and prevents HIV replication.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.